At a glance
- Originator Boehringer Ingelheim
- Class Antiarrhythmics; Ischaemic heart disorder therapies
- Mechanism of Action Alpha adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Angina pectoris; Arrhythmias; Heart failure; Hypertension
Most Recent Events
- 16 Mar 1997 Discontinued - Phase-III for Angina pectoris in Germany (IV)
- 16 Mar 1997 Discontinued - Phase-III for Arrhythmias in Germany (IV)
- 16 Mar 1997 Discontinued - Phase-III for Heart failure in Germany (IV)